We report here on the first study that effectively employed an antigen-specific recombinant viral vector (MVA-Twist-TRICOM) in combination with an OX40L fusion protein agonist (OX40L-FP) for cancer therapy. The gene discussed is TNFSF4; the disease is cancer.